Amendments to the Claims:

The following listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Withdrawn-Currently Amended) A percutaneous absorption type cerebral protective agent comprising, as an active ingredient, ~~0.1 to 30~~ 0.5 to 10 percent by mass of 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof in an aqueous base, the aqueous base comprising, based on a total amount of the aqueous base:

1 to 20 percent by mass of a water-soluble polymer,

0.01 to 20 percent by mass of a cross-linking agent,

10 to 80 percent by mass of polyhydric alcohol, and

1 to 80 percent by mass of water,

wherein the percutaneous absorption type cerebral protective agent further comprises one or more of talc, lactic acid, isopropanol and polysorbate 80.

2-5. (Canceled)

6. (Withdrawn-Currently Amended) A method of manufacturing a pharmaceutical composition, the method comprising:

combining a percutaneous absorption type pharmaceutical composition that comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof with an aqueous base in an amount of ~~0.1 to 30~~ 0.5 to 10 percent by mass, the aqueous base comprising, based on a total amount of the aqueous base:

1 to 20 percent by mass of a water-soluble polymer,

0.01 to 20 percent by mass of a cross-linking agent,

10 to 80 percent by mass of polyhydric alcohol, and

1 to 80 percent by mass of water,

wherein the percutaneous absorption type pharmaceutical composition further comprises one or more of talc, lactic acid, isopropanol and polysorbate 80.

7-10. (Canceled)

11. (Currently Amended) A method of protecting against cerebral dysfunction, comprising:

administering to a patient in need of protecting against cerebral dysfunction a percutaneous absorption type pharmaceutical composition that comprises, as an active ingredient, 3-methyl-1-phenyl-2-pyrazolin-5-one represented by the following formula:



or a medically acceptable salt thereof,

the active ingredient being present in an amount of ~~0.1 to 30~~ 0.5 to 10 percent by mass in an aqueous base, the aqueous base comprising, based on a total amount of the aqueous base:

1 to 20 percent by mass of a water-soluble polymer,

0.01 to 20 percent by mass of a cross-linking agent,

10 to 80 percent by mass of polyhydric alcohol, and

1 to 80 percent by mass of water,

wherein the percutaneous absorption type pharmaceutical composition further comprises one or more of talc, lactic acid, isopropanol and polysorbate 80.

12–15. (Canceled)

16. (Previously Presented) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition further comprises n-methyl-2-pyrrolidone or crotamiton as a dissolving agent.

17. (Previously Presented) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition further comprises tartaric acid as a speed adjuster.

18. (Previously Presented) The method according to claim 16, wherein the percutaneous absorption type pharmaceutical composition further comprises tartaric acid as a speed adjuster.

19. (Previously Presented) The method according to claim 16, wherein the dissolving agent is crotamiton.

20. (Previously Presented) The method according to claim 19, wherein the percutaneous absorption type pharmaceutical composition further comprises tartaric acid as a speed adjuster.

21. (Previously Presented) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition comprises talc.

22. (Previously Presented) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition comprises lactic acid.

23. (Previously Presented) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition comprises isopropanol.

24. (Previously Presented) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition comprises polysorbate 80.

25. (New) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition further comprises talc, lactic acid, isopropanol and polysorbate 80.

26. (New) The method according to claim 11, wherein the percutaneous absorption type pharmaceutical composition comprises 5 parts of sodium polyacrylate, 6 parts of starch acrylate, 9 parts of talc, 35 parts of concentrated glycerin, 2.3 parts of tartaric acid, 24.6 parts of water, 3 parts of 3-methyl-1-phenyl-2-pyrazolin-5-one, 5 parts of lactic acid, 5 parts of isopropanol, 1 part of isopropyl myristate, 1 part of l-menthol, 0.4 part of Polysorbate 80, 2.5 parts of polyacrylate copolymer emulsion, and 0.2 part of aluminum hydroxide gel.